United States Health

HUTCHMED (NASDAQ:HCM) will present results from two Phase III studies evaluating savolitinib combined with osimertinib in lung cancer patients at ESMO Congress 2026.

Afya (NASDAQ:AFYA) entered a binding merger agreement with Yduqs Participações S.A. to combine the two Brazilian higher education companies.

AtlasClear Holdings (NYSE:ATCH) reported fiscal 2026 revenue of $20.1 million for the year ended June 30, 2026, representing an 85% increase from the prior year.

Novartis (NYSE:NVS) won a lawsuit in Manhattan federal court after a judge dismissed claims that the company improperly used an Entresto patent listing to delay generic competition.

Bio-Techne (NASDAQ:TECH) shareholders approved the proposed acquisition by Merck KGaA, Darmstadt, Germany, at a special meeting held on September 23, 2026.

Immunovant (NASDAQ:IMVT) reported topline results from Period 1 of its proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus, with the study failing to meet its primary endpoint.

Oruka Therapeutics (NASDAQ:ORKA) reported positive Week 28 results from the Phase 2a EVERLAST-A trial evaluating ORKA-001 in patients with moderate-to-severe plaque psoriasis.

AC Immune (NASDAQ:ACIU) reported that all primary endpoints were met at week 100 in Part 1 of its Phase 2 VacSYn trial evaluating ACI-7104 in early Parkinson’s disease.

Roivant (NASDAQ:ROIV) reported topline results from Immunovant’s proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus, with the study failing to meet its primary endpoint.

IM Cannabis (NASDAQ:IMCC) signed a non-binding letter of intent to acquire 51% of Space Defense Innovations (SDI), a Poland-based company operating in the European unmanned aerial systems market.

ANI Pharmaceuticals (NASDAQ:ANIP) received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Everolimus Tablets for Oral Suspension.

Cardiol Therapeutics (NASDAQ:CRDL) reached its original enrollment target for the Phase III MAVERIC trial of CardiolRx in recurrent pericarditis and plans to expand enrollment to up to 150 patients.